Clinical Trial Update: A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of dalcetrapib in patients with stable coronary heart disease and high cardiovascular risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Heart Disease
• Dyslipidemia
• Peripheral Arterial Disease

Drugs mentioned

• Dalcetrapib (dalcetrapib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD) | Phase 3 | Status: COMPLETED